BeiGene (BGNE)
(Real Time Quote from BATS)
$188.60 USD
-1.43 (-0.75%)
Updated Aug 13, 2024 02:46 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
BeiGene, Ltd. (BGNE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$257.41 | $345.00 | $161.00 | 35.46% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for BeiGene, Ltd. comes to $257.41. The forecasts range from a low of $161.00 to a high of $345.00. The average price target represents an increase of 35.46% from the last closing price of $190.03.
Analyst Price Targets (11)
Broker Rating
BeiGene, Ltd. currently has an average brokerage recommendation (ABR) of 1.36 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on 10 recommendations.
Of the 11 recommendations deriving the current ABR, nine are Strong Buy, representing 81.82% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/BGNE.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.36 | 1.36 | 1.40 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/7/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
7/16/2024 | Nomura | Jialin Zhang | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
3/27/2024 | Not Identified | Not Identified | Hold | Hold |
2/27/2024 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
9/12/2023 | Macquarie Capital Securities | Jake Lynch | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.36 |
ABR (Last week) | 1.36 |
# of Recs in ABR | 11 |
Average Target Price | $257.41 |
LT Growth Rate | 42.30% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 253 |
Current Quarter EPS Est: | -0.80 |